Developing the next generation of oncolytic immunotherapy.
RP1 is our first Immulytic™ product to enter the clinic.
RP1 is a version of herpes simplex virus type 1, the virus that generally causes cold sores or fever bilsters, which has been engineered to replicate selectively in tumors. To aid in the direct killing of tumors and in the induction of anti-tumor immune response, RP1 is ‘armed’ with two genes, a gene encoding a fusogenic protein intended to result in enhanced cell death and enhanced immunogenicity of cell death, and a gene encoding GM-CSF, a cytokine intended to aid immune activation.
RP2 & RP3
RP2 and RP3 are derivatives of RP1 that express additional proteins. RP2 expresses an anti-CTLA-4 antibody-like molecule and RP3 additionally expresses optimized immune co-stimulatory pathway ligands. These therapeutics provide targeted delivery to the sites of immune response initiation in the tumor and draining lymph nodes with the goal of focusing systemic immune-based efficacy on tumors and limiting off target toxicity.
REGISTRATION DIRECTED Randomized, controlled Phase 2 clinical trial in ≈240 patients with CSCC. Initiating 2019